Risk factors for pneumothorax in advanced and/or metastatic soft tissue sarcoma patients during pazopanib treatment: a single-institute analysis

BACKGROUND: After the approval of pazopanib for the treatment of soft tissue sarcoma (STS), pneumothorax was reported as an unexpected adverse event during pazopanib treatment. The incidence and risk factors of pneumothorax during pazopanib treatment for STSs have not been established yet. METHODS:...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:BMC Cancer
Hauptverfasser: Nakano, Kenji, Motoi, Noriko, Tomomatsu, Junichi, Gokita, Tabu, Ae, Keisuke, Tanizawa, Taisuke, Matsumoto, Seiichi, Takahashi, Shunji
Format: Artigo
Sprache:Inglês
Veröffentlicht: BioMed Central 2016
Schlagworte:
Research Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5035441/
https://ncbi.nlm.nih.gov/pubmed/27663525
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-016-2786-z
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge